<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67163">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01947439</url>
  </required_header>
  <id_info>
    <org_study_id>BATTLE IN MULTI</org_study_id>
    <nct_id>NCT01947439</nct_id>
  </id_info>
  <brief_title>Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI</brief_title>
  <official_title>Phase 4, Prospective,Multicenter Study of Randomized Comparison of the Biolimus A9-eluting Stent With the Zotarolimus-eluting Stent in Multi-vessel PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dio</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Keimyung University Dongsan Medical Center</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The risk of restenosis in the treatment of coronary artery disease has significantly
      lessened thanks to the introduction of Drug eluting stent.

      Yet, debates on the efficacy and safety of stents in complex lesions or patients have been
      circulated.

      Recently, PCI in multiple lesions is universally performed with the development of effective
      stents in various kinds in the clinics.

      However, a randomized study  is rare for  multi-vessel coronary artery disease in real
      procedural environments.

      The primary purpose of this study is to evaluate the clinical progress of biolimus
      A9-eluting stent and zotarolimus-eluting stent in multi-vessel coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients who need multi-vessel stenting with multi-vessel coronary artery disease will
      be enrolled.Each randomization of the enrolled subjects will be done 1:1 (biolimus
      A9-eluting stent : zotarolimus-eluting stent). Randomization will be stratified by two
      factors: Diabetes mellitus and Acute coronary syndrome.Clinical follow-up will occur at the
      following time points; 1 month, 1 year and 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>2-year composite end points</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All cause death, non fatal myocardial infarction, any revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-cardiac death</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non fatal myocardial infarction</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Multivessel Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Biolimus A9 eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>biolimus A9 stent( Biomatrix or Biomatrix Flex) will be placed in  under Percutaneous Transluminal Coronary Angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zotarolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zotarolimus eluting stent (Resolute Integrity) will be placed in under Percutaneous Transluminal Coronary Angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Transluminal Coronary Angioplasty</intervention_name>
    <description>Percutaneous Transluminal coronary angioplasty will be performed in both of randomized groups of  biolimus A9 eluting stent and zotarolimus eluting stent</description>
    <arm_group_label>Biolimus A9 eluting stent</arm_group_label>
    <arm_group_label>Zotarolimus-eluting stent</arm_group_label>
    <other_name>-Resolute Integrity</other_name>
    <other_name>-Biomatrix</other_name>
    <other_name>-Biomatrix Flex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who need multi-vessel stenting with multi-vessel disease

          -  patients with signed informed consent

        Exclusion Criteria:

          -  known contraindication to any of the following medications: Aspirin,clopidogrel,
             heparin, contrast agent, Biolimus or Zotarolimus group

          -  Cardiogenic shock

          -  Patients with primary PCI

          -  Pregnant women or women with potential childbearing

          -  End-stage diseases with life expectancy shorter than 2 years

          -  patients with other Drug eluting stents implanted

          -  Patients requiring modification of antiplatelet agents for planned major surgery
             within the first 12 months after the enrollment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Wook Nam, Postdoctoral</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang-Wook Nam, Postdoctoral</last_name>
    <phone>82-53-250-8015</phone>
    <email>namcwcv@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Woong Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jin-Bae Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Fatima Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bong-Ryeol Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KyungPook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jang-Hoon Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 23, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Keimyung University Dongsan Medical Center</investigator_affiliation>
    <investigator_full_name>NAM, Chang-Wook</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>multivessel stenting</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
